NewLimit is  treating age-related disease to extend human healthspan

By conducting in-house research.
By collaborating with the world’s top academic and clinical experts.
By translating scientific discoveries into real world products.

NewLimit is developing epigenetic reprogramming medicines to treat diseases with large unmet needs.

NewLimit is composed of experts across cell biology, genomics, computational biology, machine learning, and operations.

We collaborate across disciplines to design  experiments and models that build upon each other.

We work iteratively and move quickly to build technologies and generate enabling data. Each experiment informs the next. NewLimit’s organizational strategy and operations team works to continually increase the efficiency of our product progress per unit time, dollars spent, and equity burned.